These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12669735)

  • 1. Preclinical evidence of normal bone with alendronate.
    Hayes WC; Shea M; Rodan GA
    Int J Clin Pract Suppl; 1999 Apr; 101():9-13. PubMed ID: 12669735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
    Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
    Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of alendronate on bone turnover and bone quality.
    Meunier PJ; Arlot M; Chavassieux P; Yates AJ
    Int J Clin Pract Suppl; 1999 Apr; 101():14-7. PubMed ID: 12669736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge.
    Spadaro JA; Damron TA; Horton JA; Margulies BS; Murray GM; Clemente DA; Strauss JA
    J Orthop Res; 2006 May; 24(5):936-44. PubMed ID: 16609966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
    Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P
    Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical safety profile of alendronate.
    Peter C; Rodan GA
    Int J Clin Pract Suppl; 1999 Apr; 101():3-8. PubMed ID: 12669734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alendronate: preclinical studies.
    Rodan GA
    Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):50S-52S. PubMed ID: 9273938
    [No Abstract]   [Full Text] [Related]  

  • 9. Preventive effects of withaferin A isolated from the leaves of an Indian medicinal plant Withania somnifera (L.): comparisons with 17-β-estradiol and alendronate.
    Khedgikar V; Ahmad N; Kushwaha P; Gautam J; Nagar GK; Singh D; Trivedi PK; Mishra PR; Sangwan NS; Trivedi R
    Nutrition; 2015 Jan; 31(1):205-13. PubMed ID: 25466667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
    Leu CT; Luegmayr E; Freedman LP; Rodan GA; Reszka AA
    Bone; 2006 May; 38(5):628-36. PubMed ID: 16185944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate: preclinical studies.
    Rodan GA
    J Clin Rheumatol; 1997 Apr; 3(2 Suppl):34-6. PubMed ID: 19078150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts.
    Woo JT; Kawatani M; Kato M; Shinki T; Yonezawa T; Kanoh N; Nakagawa H; Takami M; Lee KH; Stern PH; Nagai K; Osada H
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4729-34. PubMed ID: 16537392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of alendronate on bone resorption of autogenous free bone grafts in rats.
    Altundal H; Sayrak H; Yurtsever E; Göker K
    J Oral Maxillofac Surg; 2007 Mar; 65(3):508-16. PubMed ID: 17307600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation.
    Marie PJ
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alendronate prevents bone loss and improves tendon-to-bone repair strength in a canine model.
    Thomopoulos S; Matsuzaki H; Zaegel M; Gelberman RH; Silva MJ
    J Orthop Res; 2007 Apr; 25(4):473-9. PubMed ID: 17205555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.
    Christopoulou GE; Stavropoulou A; Anastassopoulos G; Panteliou SD; Papadaki E; Karamanos NK; Panagiotopoulos E
    J Pharm Biomed Anal; 2006 Jun; 41(3):891-7. PubMed ID: 16488571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
    Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D
    Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
    Azuma Y; Sato H; Oue Y; Okabe K; Ohta T; Tsuchimoto M; Kiyoki M
    Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
    Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
    Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rat model for testing pharmacologic treatments of pressure-related bone loss.
    Astrand J; Skripitz R; Skoglund B; Aspenberg P
    Clin Orthop Relat Res; 2003 Apr; (409):296-305. PubMed ID: 12671515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.